[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-352100-105":59,"doc-detail-352100-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","molecular-characteristics-and-clinicopathology-of-ctnnb1-mutated-endometrial-cancer-implications-for-fertility-sparing-management-in-young-women","Molecular characteristics and clinicopathology of CTNNB1-mutated endometrial cancer - Implications for fertility-sparing management in young women","","Endometrial cancer incidence is rising in young women needing fertility preservation, making molecular biomarkers critical for outcome improvement. This retrospective study evaluates CTNNB1 mutations in endometrial cancer and tests whether CTNNB1 can serve as a molecular marker for infertility-sparing management. Molecular landscapes and TCGA-based classification are assessed using targeted next-generation sequencing and immunohistochemistry, comparing clinicopathological features and progestin treatment responses in fertility-sparing therapy patients.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/molecular-characteristics-and-clinicopathology-of-ctnnb1-mutated-endometrial-cancer-implications-for-fertility-sparing-management-in-young-women/352100/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/molecular-characteristics-and-clinicopathology-of-ctnnb1-mutated-endometrial-cancer-implications-for-fertility-sparing-management-in-young-women/352100.png","ImageObject",300,407,{"name":92,"@type":93},"dhado","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-07","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What molecular factor does the study focus on in endometrial cancer?","Question",{"text":112,"@type":113},"The study focuses on CTNNB1 mutations and how they relate to molecular characteristics and clinicopathological features in endometrial cancer.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were molecular profiling and classification performed?",{"text":117,"@type":113},"Molecular landscapes and TCGA-based molecular classification were analyzed using targeted next-generation sequencing and immunohistochemistry.",{"name":119,"@type":110,"acceptedAnswer":120},"What does the study report about progestin response in CTNNB1-mutated patients?",{"text":121,"@type":113},"Patients with CTNNB1 mutations showed a poor response to progestin therapy, potentially linked to reduced progesterone receptor expression associated with β-catenin nuclear expression.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},352100,1790728024,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},5909893218464,"https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","Li etal. BMC Cancer (2026) 26:1025 BMC Cancer  \n[https://doi.org/10.1186/s12885-026-16370-y](https://doi.org/10.1186/s12885-026-16370-y)  \nRESEARCH Open Access  \nMolecular characteristics and clinicopathology  of CTNNB1-mutated endometrial cancer: Implications for fertility-sparing management in young women  \nWen-Qi Li 1, Hai-Xia Wu1, Han-Bo Li 1, Guang-Nan Shuai2, Qing Zhang1 andYan Shen1*  \nAbstract  \nBackground The incidence rate of endometrial cancer (EC) is increasing among young women who require fertility preservation. The identification of molecular biomarkers can improve clinical outcomes in these patients. This study evaluated the role of CTNNB1 mutations in EC and whether the CTNNB1 gene can serve as a molecular marker infertility-sparing management.  \nMethods Retrospective cohorts of patients with pathologically confirmed EC were included in the study. The molecular landscape and TCGA-based molecular classification were analyzed through targeted next-generation sequencing and immunohistochemistry. The clinicopathological and molecular characteristics of CTNNB1-mutated and CTNNB1-wild-type patients were assessed. For young patient who received fertility-sparing treatment (FST), the responses to progestin treatment were evaluated.  \nResults CTNNB1 mutations were significantly more common in the age group ≤40 years than in the age group >40 years, indicating that CTNNB1 had a significant role in young patients with EC seeking fertility preservation. Most cases carrying CTNNB1 mutations were in the no specific molecular profile group. The most frequent CTNNB1 hotspot mutations were Ser37Phe on exon3 (16 . 13%) . Moreover, CTNNB1 mutations were significantly associated with higher rates of endometrioid EC (p = 0 . 0001) and earlier stages (FIGO I or II) than the absence of mutations  \n(p = 0 . 0457) . Nonetheless, there were no significant differences in other pathological risk factors between the mutant and wild-type groups. The immunohistochemical expression of β-catenin can be used as a surrogate for CTNNB1 mutation status; nonetheless, specificity was associated with the frequency of CTNNB1 mutations. Patients with CTNNB1 mutations showed poor response to progestin treatment, possibly because of the reduced expression of progesterone receptors since the nuclear expression of β-catenin in the endometrium was negatively correlated with progesterone receptor expression.  \nConclusions CTNNB1 status in EC can help predict the response to fertility-sparing treatment, allowing early stratification and risk assignment.  \n*Correspondence: Yan Shen [serina_shen@163.com](serina_shen@163.com)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026, modified publication 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercialNoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://cre](http://cre)[ativecommons.org/licenses/by-nc-nd/4.0/](ativecommons.org/licenses/by-nc-nd/4.0/.)[.](ativecommons.org/licenses/by-nc-nd/4.0/.)  \nLi et al. BMC Cancer (2026) 26:1025 Page 2 of 11  \nKeywords Endometrial cancer, CTNNB1, β-catenin, Fertility-sp","cbCaioKUHu7GajP6","https://ap.wps.com/l/cbCaioKUHu7GajP6","pdf",2150576,11,"English","# Abstract\n# Introduction\n## Fertility-sparing treatment context\n## Molecular classification background\n## CTNNB1 and β-catenin role\n# Methods\n# Results\n# Conclusions","[{\"question\":\"What molecular factor does the study focus on in endometrial cancer?\",\"answer\":\"The study focuses on CTNNB1 mutations and how they relate to molecular characteristics and clinicopathological features in endometrial cancer.\"},{\"question\":\"How were molecular profiling and classification performed?\",\"answer\":\"Molecular landscapes and TCGA-based molecular classification were analyzed using targeted next-generation sequencing and immunohistochemistry.\"},{\"question\":\"What does the study report about progestin response in CTNNB1-mutated patients?\",\"answer\":\"Patients with CTNNB1 mutations showed a poor response to progestin therapy, potentially linked to reduced progesterone receptor expression associated with β-catenin nuclear expression.\"}]","Molecular characteristics and clinicopathology of CTNNB1-mutated endometrial cancer - Implications for fertility-sparing management in young women | PDF",1790097692,28,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/56d5d5da667ab685703fb6786c7f2960.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d69e83edff08c0cae70695ac4541045c.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7a51f39c8f136d65a26deb6715db7ca8.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/872ad82b668440c84879cfd7344b4d79.webp",980,1306]